| For: | Bai J, Chen WB, Zhang XY, Kang XN, Jin LJ, Zhang H, Wang ZY. HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling. World J Stem Cells 2020; 12(1): 87-99 [PMID: 32110277 DOI: 10.4252/wjsc.v12.i1.87] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v12/i1/87.htm |
| Number | Citing Articles |
| 1 |
Wentao Si, Chen Kan, Leisheng Zhang, Feifei Li. Role of RUNX2 in breast cancer development and drug resistance (Review). Oncology Letters 2023; 25(5) doi: 10.3892/ol.2023.13762
|
| 2 |
Jin‐Dan Kai, Liang‐Hao Cheng, Bin‐Feng Li, Kai Kang, Fei Xiong, Jing‐Chun Fu, Sheng Wang. MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis. Cell Biology International 2022; 46(12) doi: 10.1002/cbin.11894
|
| 3 |
Jiwei Zhang, Wenjuan Gan, Ru Peng, Lei Lu, Weiqing Lu, Jiamei Liu. Activation of the mTOR pathway promotes neurite growth through upregulation of CD44 expression. Journal of International Medical Research 2023; 51(6) doi: 10.1177/03000605231178510
|
| 4 |
Loredana G. Marcu, Leyla Moghaddasi, Eva Bezak. Cannot Target What Cannot Be Seen: Molecular Imaging of Cancer Stem Cells. International Journal of Molecular Sciences 2023; 24(2) doi: 10.3390/ijms24021524
|
| 5 |
Jianjie Li, Xiangmei Zhang, Xueliang Liu, Xiangmin Ma, Yanfang Wang, Yunjiang Liu. JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway. Expert Review of Anticancer Therapy 2024; 24(10) doi: 10.1080/14737140.2024.2394167
|
| 6 |
Yue Su, Bolun Zhang, Ruowei Sun, Wenfang Liu, Qubo Zhu, Xun Zhang, Rongrong Wang, Chuanpin Chen. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Delivery 2021; 28(1) doi: 10.1080/10717544.2021.1938756
|
| 7 |
Feng Ju, Manar M. Atyah, Nellie Horstmann, Sheraz Gul, Razi Vago, Christiane J. Bruns, Yue Zhao, Qiong-Zhu Dong, Ning Ren. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Research & Therapy 2022; 13(1) doi: 10.1186/s13287-022-02904-1
|
| 8 |
Zhen Luo, Mingfu Tian, Ge Yang, Qiaoru Tan, Yubing Chen, Geng Li, Qiwei Zhang, Yongkui Li, Pin Wan, Jianguo Wu. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01080-1
|
| 9 |
Yan Xu, Tao Hu, Huizhen Ding, Yi Yuan, Rui Chen. miR-485-5p alleviates obstructive sleep apnea syndrome with hypertension by inhibiting PI3K/AKT signaling pathway via downregulating HIF3A expression. Sleep and Breathing 2023; 27(1) doi: 10.1007/s11325-022-02580-8
|
| 10 |
|
| 11 |
Guofang Chen, Binya Liu, Shasha Yin, Shuangdi Li, Yu’e Guo, Mengfei Wang, Kai Wang, Xiaoping Wan. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. Oncogenesis 2020; 9(9) doi: 10.1038/s41389-020-00265-z
|
| 12 |
Xianjing Chu, Wentao Tian, Jiaoyang Ning, Gang Xiao, Yunqi Zhou, Ziqi Wang, Zhuofan Zhai, Guilong Tanzhu, Jie Yang, Rongrong Zhou. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01851-y
|
| 13 |
Ruhan A, Naoto Kunimura, Shoko Tominaga, Erika Hirata, Shunya Nishioka, Misato Uesugi, Rion Yamazaki, Hideto Ueki, Koichi Kitagawa, Masato Fujisawa, Toshiro Shirakawa. A recombinant adenovirus vector containing the synNotch receptor gene for the treatment of triple-negative breast cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1147668
|
| 14 |
Xiaoxu Wei, Yunhua Chen, Xianjie Jiang, Miao Peng, Yiduo Liu, Yongzhen Mo, Daixi Ren, Yuze Hua, Boyao Yu, Yujuan Zhou, Qianjin Liao, Hui Wang, Bo Xiang, Ming Zhou, Xiaoling Li, Guiyuan Li, Yong Li, Wei Xiong, Zhaoyang Zeng. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Molecular Cancer 2021; 20(1) doi: 10.1186/s12943-020-01288-1
|
| 15 |
Hoon Sik Choi, Young Shin Ko, Hana Jin, Ki Mun Kang, In Bong Ha, Hojin Jeong, Haa-Na Song, Hye Jung Kim, Bae Kwon Jeong. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro. Molecules 2021; 26(17) doi: 10.3390/molecules26175118
|
| 16 |
Tuna Onal, Mustafa Oztatlici, Melike Ozgul-Onal, Hülya Birinci, Mahmud Kemal Ozbilgin, Vissun Sevinç Inan. Рапаміцин знижує експресію рецепторів гіалуронану в клітинних лініях раку молочної залози MCF-7 та MDA-MB-231. Practical oncology 2022; 4(3-4) doi: 10.22141/2663-3272.4.3-4.2021.250854
|
| 17 |
Barbara Ruszkowska-Ciastek, Katarzyna Kwiatkowska, Dorinda Marques-da-Silva, Ricardo Lagoa. Cancer Stem Cells from Definition to Detection and Targeted Drugs. International Journal of Molecular Sciences 2024; 25(7) doi: 10.3390/ijms25073903
|
| 18 |
Cheng-Xian Ma, Jie Chen, Jian-Lin Wang, Shuai Pei, Zhao-Jun Zhang, Yu-Si Xie, Xia He. Co-expression of cancer stem cell markers CD24 and CD133 in gastric cancer tissues: Clinicopathological and prognostic significance. World Journal of Stem Cells 2026; 18(1): 114891 doi: 10.4252/wjsc.v18.i1.114891
|
| 19 |
Tianshu Zhang, Huimin Zhou, Kexin Wang, Xiaowei Wang, Mengyan Wang, Wenxia Zhao, Xiaoming Xi, Yang Li, Meilian Cai, Wuli Zhao, Yanni Xu, Rongguang Shao. Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomedicine & Pharmacotherapy 2022; 147 doi: 10.1016/j.biopha.2022.112616
|
| 20 |
Amal Qattan. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease. International Journal of Molecular Sciences 2020; 21(23) doi: 10.3390/ijms21238905
|
| 21 |
Jingjing Gu, Dandan Chen, Zhiqiang Li, Yongliang Yang, Zhaoming Ma, Guanhong Huang. Prognosis assessment of CD44+/CD24− in breast cancer patients: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics 2022; 306(4) doi: 10.1007/s00404-022-06402-w
|
| 22 |
Shichun Wang, Pengyu Zhang, Ekansh Mittal. Bioinformatics Analysis Identifies EPAS1 as a Novel Prognostic Marker Correlated with Immune Infiltration in Acute Myeloid Leukemia. Disease Markers 2023; 2023 doi: 10.1155/2023/6072782
|
| 23 |
Ain Zubaidah Ayob, Thamil Selvee Ramasamy. Prolonged hypoxia switched on cancer stem cell-like plasticity in HepG2 tumourspheres cultured in serum-free media. In Vitro Cellular & Developmental Biology - Animal 2021; 57(9) doi: 10.1007/s11626-021-00625-y
|
| 24 |
Eddy Saad, Marc Machaalani, David F. McDermott, Toni K. Choueiri. The clinical landscape of HIF2α inhibitors in oncology. Nature Reviews Clinical Oncology 2026; 23(7) doi: 10.1038/s41571-026-01145-y
|
| 25 |
Ernestina Marianna De Francesco, Francesca Cirillo, Veronica Vella, Antonino Belfiore, Marcello Maggiolini, Rosamaria Lappano. Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets 2022; 26(6) doi: 10.1080/14728222.2022.2094762
|
| 26 |
Hamid Lotfimehr, Narges Mardi, Samaneh Narimani, Hamid Tayefi Nasrabadi, Mohammad Karimipour, Emel Sokullu, Reza Rahbarghazi. mTORsignalling pathway in stem cell bioactivities and angiogenesis potential. Cell Proliferation 2023; 56(12) doi: 10.1111/cpr.13499
|
| 27 |
Suvadeep Mal, Thakur Gurjeet Singh, Ajit Kumar Bishoyi, Kakarla Pakeeraiah, Preetesh Kumar Panda, Monalisa Mahapatra, Suvadra Das, Roshan Kumar, Sudhir Kumar Paidesetty, Partha Roy. Biosafe chitosan/hyaluronic acid dual decorated diosmetin nano-gold selectively targets CD-44 and DNA gyrase to overcome drug resistance in triple negative breast cancer and AMR superbugs. Journal of Drug Delivery Science and Technology 2026; 122 doi: 10.1016/j.jddst.2026.108444
|
| 28 |
Karolina Kozal, Anna Krześlak. The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy. Cancers 2022; 14(18) doi: 10.3390/cancers14184518
|
| 29 |
Ilhaam Ayaz Durrani, Peter John, Attya Bhatti, Jahangir Sarwar Khan. Network medicine based approach for identifying the type 2 diabetes, osteoarthritis and triple negative breast cancer interactome: Finding the hub of hub genes. Heliyon 2024; 10(17) doi: 10.1016/j.heliyon.2024.e36650
|
| 30 |
Zhuoling Zou, Tinglan Luo, Xinyuan Wang, Bin Wang, Qing Li. Exploring the interplay between triple‐negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies. Journal of Cellular Physiology 2024; 239(8) doi: 10.1002/jcp.31278
|
| 31 |
Chen Zhang, Shu Xu, Chuanzheng Yin, Shaobo Hu, Pian Liu. The role of the mTOR pathway in breast cancer stem cells (BCSCs): mechanisms and therapeutic potentials. Stem Cell Research & Therapy 2025; 16(1) doi: 10.1186/s13287-025-04218-4
|
| 32 |
Binjie Huang, Xin Yan, Yumin Li. Cancer Stem Cell for Tumor Therapy. Cancers 2021; 13(19) doi: 10.3390/cancers13194814
|
| 33 |
Felipe P. de Oliveira, Mateus L. Nogueira, Alexandre F.C. Galvão, Rosane B. Dias, Daniel P. Bezerra. Translational drugs targeting cancer stem cells in triple-negative breast cancer. Molecular Therapy Oncology 2025; 33(3) doi: 10.1016/j.omton.2025.201008
|
| 34 |
Lochana Kovale, Manish Kumar Singh, Joungmok Kim, Joohun Ha. Role of Autophagy and AMPK in Cancer Stem Cells: Therapeutic Opportunities and Obstacles in Cancer. International Journal of Molecular Sciences 2024; 25(16) doi: 10.3390/ijms25168647
|
| 35 |
Hong-My Nguyen, Wyatt Paulishak, Mariam Oladejo, Laurence Wood. Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Breast Cancer 2023; 30(2) doi: 10.1007/s12282-022-01415-4
|
| 36 |
Charles B. Nguyen, Eugene Oh, Piroz Bahar, Ulka N. Vaishampayan, Tobias Else, Ajjai S. Alva. Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma. Cancers 2024; 16(3) doi: 10.3390/cancers16030601
|
| 37 |
Stefania Nobili, Antonella Mannini, Astrid Parenti, Chiara Raggi, Andrea Lapucci, Giovanna Chiorino, Sara Paccosi, Paola Di Gennaro, Vania Vezzosi, Paolo Romagnoli, Tommaso Susini, Marcella Coronnello. Establishment and characterization of a new spontaneously immortalized ER−/PR−/HER2+ human breast cancer cell line, DHSF-BR16. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-87362-0
|
| 38 |
Sepideh Mirzaei, Hojjat Samareh Fekri, Farid Hashemi, Kiavash Hushmandi, Reza Mohammadinejad, Milad Ashrafizadeh, Ali Zarrabi, Manoj Garg. Venom peptides in cancer therapy: An updated review on cellular and molecular aspects. Pharmacological Research 2021; 164 doi: 10.1016/j.phrs.2020.105327
|
| 39 |
Wenmin Chen, Lu Zhang, Suling Liu, Ceshi Chen. Advances in Biomarkers and Endogenous Regulation of Breast Cancer Stem Cells. Cells 2022; 11(19) doi: 10.3390/cells11192941
|
| 40 |
Zhi-Min Deng, Gan-Hong Chen, Fang-Fang Dai, Shi-Yi Liu, Dong-Yong Yang, An-Yu Bao, Yan-Xiang Cheng, Ritu Kulshreshtha. The clinical value of miRNA-21 in cervical cancer: A comprehensive investigation based on microarray datasets. PLOS ONE 2022; 17(4) doi: 10.1371/journal.pone.0267108
|
| 41 |
Mohammed Hussein Assi. Hypoxia-inducible Factors: Molecular Basis and Clinical Implications. Mustansiriya Medical Journal 2023; 22(2) doi: 10.4103/mj.mj_38_23
|
| 42 |
Wang Manni, Wu Min. Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. MedComm 2022; 3(4) doi: 10.1002/mco2.176
|
| 43 |
Jian Zhan, Manfred Jücker. The Role of PI3K/AKT/mTOR Signaling in Tumor Radioresistance and Advances in Inhibitor Research. International Journal of Molecular Sciences 2025; 26(14) doi: 10.3390/ijms26146853
|
| 44 |
Jingwei Xu, Di Xue, Yang Li, Jianwen Zhou, Hongyue Chen, Li Fan. Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells. Heliyon 2024; 10(6) doi: 10.1016/j.heliyon.2024.e27629
|
| 45 |
Rami Nassir, Ghada Esheba, Hanan M. Abd Elmoneim, Ahlam S. Altowairqi, Ghassan Nouman. Expression and Clinical Significance of <i>PIK3CA</i>, <i>c-MET</i> and <i>c-KIT</i> Mutations in Saudi Breast Cancer Patients. Advances in Breast Cancer Research 2021; 10(03) doi: 10.4236/abcr.2021.103005
|
| 46 |
Jing Lu, Haotian Zhang, Xiaoyu Gu, Yonghui Liu, Chengwen Zhao, Xudong Wang. Identification of key genes regulating colorectal cancer stem cell characteristics by bioinformatics analysis. Medicine 2025; 104(22) doi: 10.1097/MD.0000000000040910
|
| 47 |
Christina Karapouliou, Elisyazaviera M. Faizul, Vinothini Rajeeve, Pedro R. Cutillas, Andrew W. Stoker. HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-23141-5
|
| 48 |
Yue Lu, Dongfang Cheng, Baohua Niu, Xiuzhi Wang, Xiaxia Wu, Aiping Wang. Properties of Poly (Lactic-co-Glycolic Acid) and Progress of Poly (Lactic-co-Glycolic Acid)-Based Biodegradable Materials in Biomedical Research. Pharmaceuticals 2023; 16(3) doi: 10.3390/ph16030454
|
| 49 |
Mohammed Kaleem, Maryam Perwaiz, Suza Mohammad Nur, Abdulrasheed O. Abdulrahman, Wasim Ahmad, Fahad A. Al-Abbasi, Vikas Kumar, Mohammad Amjad Kamal, Firoz Anwar. Epigenetics of Triple-Negative Breast Cancer via Natural Compounds. Current Medicinal Chemistry 2022; 29(8) doi: 10.2174/0929867328666210707165530
|
| 50 |
Qi-Ying Yu, Zhi-Wen Wang, Meng-Ying Zhou, Shang-Fu Li, Xing-Hua Liao. MAGE-A3 regulates tumor stemness in gastric cancer through the PI3K/AKT pathway. Aging 2022; doi: 10.18632/aging.204373
|
| 51 |
Jing-Hua Liu, Wen-Ting Li, Yue Yang, Yan-Bo Qi, Yu Cheng, Jia-Hui Wu. MiR-526b-3p Attenuates Breast Cancer Stem Cell Properties and Chemoresistance by Targeting HIF-2α/Notch Signaling. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.696269
|
| 52 |
Shumin Sun, Nailin Yang, Zifan Pei, Fei Gong, Liang Cheng. Biomedical engineering targeting cancer stem cells to reinforce cancer therapy. Coordination Chemistry Reviews 2025; 530 doi: 10.1016/j.ccr.2025.216494
|
| 53 |
Kirti S. Prabhu, Shilpa Kuttikrishnan, Zahwa Mariyam, Ummu Habeeba, Anu Jayanthi Panicker, Tariq Masoodi, Kulsoom Junejo, Shahab Uddin. PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(12) doi: 10.1007/s00210-025-04297-3
|
| 54 |
Gang Sun, Jin Zhang, Shuai Wu, Yun Liu. Experimental study on nuclear-targeted plasmid-based short hairpin RNA (ShRNA) to hypoxia inducible factor-1α (PshHIF-1α) PshHIF-1α nano-drug carrier system for breast cancer treatment in rats. Materials Express 2021; 11(7) doi: 10.1166/mex.2021.2029
|
| 55 |
Guangpeng He, Xueqiang Peng, Shibo Wei, Shuo Yang, Xinyu Li, Mingyao Huang, Shilei Tang, Hongyuan Jin, Jiaxing Liu, Sheng Zhang, Hongyu Zheng, Qing Fan, Jingang Liu, Liang Yang, Hangyu Li. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Molecular Cancer 2022; 21(1) doi: 10.1186/s12943-021-01440-5
|
| 56 |
Yuanyuan Yan, Miao He, Lin Zhao, Huizhe Wu, Yanyun Zhao, Li Han, Binbin Wei, Dongman Ye, Xuemei Lv, Yan Wang, Weifan Yao, Haishan Zhao, Bo Chen, Zining Jin, Jian Wen, Yan Zhu, Tao Yu, Feng Jin, Minjie Wei. A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. Cell Death & Differentiation 2022; 29(9) doi: 10.1038/s41418-022-00963-8
|
| 57 |
Nan Che, Zhaoting Yang, Xingzhe Liu, Mengxuan Li, Ying Feng, Chengye Zhang, Chao Li, Yan Cui, Yanhua Xuan. Suppression of LETM1 inhibits the proliferation and stemness of colorectal cancer cells through reactive oxygen species–induced autophagy. Journal of Cellular and Molecular Medicine 2021; 25(4) doi: 10.1111/jcmm.16169
|
| 58 |
Ching-I Chen, Deng-Yu Kuo, Hui-Yen Chuang. FASN inhibition shows the potential for enhancing radiotherapy outcomes by targeting glycolysis, AKT, and ERK pathways in breast cancer. International Journal of Radiation Biology 2025; 101(3) doi: 10.1080/09553002.2024.2446585
|
| 59 |
Xing Zhen, Hack Sun Choi, Ji-Hyang Kim, Su-Lim Kim, Ren Liu, Yu-Chan Ko, Bong-Sik Yun, Dong-Sun Lee. Caudatin Isolated from Cynanchum auriculatum Inhibits Breast Cancer Stem Cell Formation via a GR/YAP Signaling. Biomolecules 2020; 10(6) doi: 10.3390/biom10060925
|
| 60 |
Hui Xu, Fengxia Zhang, Xiaokang Gao, Qiwang Zhou, Linhai Zhu. Fate decisions of breast cancer stem cells in cancer progression. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.968306
|
| 61 |
Yiming Xu, Ziyi Bai, Tianxia Lan, Chenying Fu, Ping Cheng. CD44 and its implication in neoplastic diseases. MedComm 2024; 5(6) doi: 10.1002/mco2.554
|
| 62 |
Dingwen Zhong, Yonghui Liao, Wenhui Chen, Xianyu Huang, Jiaxin Liu, Zheng Wang. TYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarization. Journal of Gastroenterology and Hepatology 2024; 39(12) doi: 10.1111/jgh.16783
|
| 63 |
Wanling Chen, Yang Wang, Zhengduo Yao, Ting Gu, Yuhua Hu, Nannan Leng, Chunye Zhang, Zhen Tian, Jiang Li. ECT2+ cell group acts as cancer stem cell in malignant pleomorphic adenoma. npj Precision Oncology 2025; 9(1) doi: 10.1038/s41698-025-00974-x
|
| 64 |
Identification of Flavonoid-based Hypoxia-inducible Factor-2 Alpha Inhibitors for the Treatment of Breast Cancer– In silico and In vitro Evidence. Anti-Cancer Agents in Medicinal Chemistry 2025; 25(17) doi: 10.2174/0118715206377378250414052656
|
| 65 |
Ritu Soni, Mithun Singh Rajput, Jigna Shah. Advancements in the Treatment and Prevention of Breast Cancer. 2026; doi: 10.1016/B978-0-443-33653-9.00015-6
|
| 66 |
Yiming Yang, Xiaohui Liu, Yang Zhang, Hao Dai, Jianglun Shen, Fen Hu, Haifeng Cai, Jinyin Yan. Superparamagnetic Iron Oxide Nanoparticles Directed miRNA-34b-RNA-Binding Proteins T Cell to Restrict Intracellular Antigen-1-Stress Granules (TIA-1-SG) in Breast Cancer Chemotherapy. Science of Advanced Materials 2021; 13(10) doi: 10.1166/sam.2021.4100
|
| 67 |
Hamid A. Bakshi, Michella Mkhael, Hakkim L. Faruck, Asad Ullah Khan, Alaa A.A. Aljabali, Vijay Mishra, Mohamed El-Tanani, Nitin B. Charbe, Murtaza M. Tambuwala. Cellular signaling in the hypoxic cancer microenvironment: Implications for drug resistance and therapeutic targeting. Cellular Signalling 2024; 113 doi: 10.1016/j.cellsig.2023.110911
|